These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 19470739)

  • 1. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
    Khanna C; Gordon I
    Clin Cancer Res; 2009 Jun; 15(11):3645-7. PubMed ID: 19470723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
    Yancey MF; Merritt DA; White JA; Marsh SA; Locuson CW
    J Vet Pharmacol Ther; 2010 Apr; 33(2):154-61. PubMed ID: 20444040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
    Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
    Taylor F; Gear R; Hoather T; Dobson J
    J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
    Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
    J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
    Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
    J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
    Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.